Evidence map›Paper›PMID 41060473›Full record

ReviewDiscover oncology2025

Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors.

Lihao Wang, Dandan Wei, Shanshan Li, Shiqing Jiang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lihao WangDepartment of Spleen, Stomach, Liver and Gallbladder Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
Dandan WeiAcupuncture Pain Department, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
Shanshan LiEndocrinology Department, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
Shiqing JiangHematology Oncology Department, The First Affiliated Hospital of Henan University of Chinese Medicine, No.19 Renmin Road, Zhengzhou City, 450000, Henan Province, China. jiangshiqing66@126.com.

Funding

Scientific research project of Henan National Center for inheritance and innovation of traditional Chinese medicine in 2023 2023ZXZX1067
6 · The paper itself

Abstract

KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS

Indexed as

BiomarkersKRAS mutation-targeted inhibitorsResistance mechanisms

Identifiers

PMID41060473
PMCPMC12508421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.